Skip to main navigation Skip to search Skip to main content

Micronutritional supplementation with a holoBLG-based FSMP (food for special medical purposes)-lozenge alleviates allergic symptoms in BALB/c mice: Imitating the protective farm effect

  • Sheriene Moussa Afify
  • , Andreas Regner
  • , Luis F Pacios
  • , Bart R Blokhuis
  • , Sebastian A Jensen
  • , Frank A Redegeld
  • , Isabella Pali-Schöll
  • , Karin Hufnagl
  • , Rodolfo Bianchini
  • , Sonja Guethoff
  • , Matthias F Kramer
  • , Alessandro Fiocchi
  • , Zdenek Dvorak
  • , Erika Jensen-Jarolim
  • , Franziska Roth-Walter
  • Medical University Vienna and University of Vienna
  • Technical University of Madrid
  • Medical University of Vienna
  • Bencard Allergie GmbH
  • Childrens Hospital Bambino Gesù
  • Palacky University

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Background: Previously, the protective farm effect was imitated using the whey protein beta-lactoglobulin (BLG) that is spiked with iron-flavonoid complexes. Here, we formulated for clinical translation a lozenge as food for special medical purposes (FSMP) using catechin-iron complexes as ligands for BLG. The lozenge was tested in vitro and in a therapeutical BALB/c mice model. Methods: Binding of iron-catechin into BLG was confirmed by spectroscopy and docking calculations. Serum IgE binding of children allergic or tolerating milk was assessed to loaded (holo-) versus empty (apo-) BLG and for human mast cell degranulation. BLG and Bet v 1 double-sensitized mice were orally treated with the holoBLG or placebo lozenge, and immunologically analysed after systemic allergen challenge. Human PBMCs of pollen allergic subjects were flow cytometrically assessed after stimulation with apoBLG or holoBLG using catechin-iron complexes as ligands. Results: One major IgE and T cell epitope were masked by catechin-iron complexes, which impaired IgE binding of milk-allergic children and degranulation of mast cells. In mice, only supplementation with the holoBLG lozenge reduced clinical reactivity to BLG and Bet v 1, promoted Tregs, and suppressed antigen presentation. In allergic subjects, stimulation of PBMCs with holoBLG led to a significant increase of intracellular iron in circulating CD14+ cells with significantly lower expression of HLADR and CD86 compared to their stimulation with apoBLG. Conclusion: The FSMP lozenge targeted antigen presenting cells and dampened immune activation in human immune cells and allergic mice in an antigen-non-specific manner, thereby conferring immune resilience against allergic symptoms.

Original languageEnglish
Pages (from-to)426-441
JournalClinical and Experimental Allergy
Volume52
Issue number3
Early online date13 Nov 2021
DOIs
Publication statusPublished - Mar 2022

Bibliographical note

Funding Information:
The study was supported by Biomedical International R+D GmbH, Vienna, Austria and Bencard Allergie GmbH, Munich, Germany and in part by the Austrian Science Fund FWF, grant SFB F4606‐B28.

Publisher Copyright:
© 2021 The Authors. Clinical & Experimental Allergy published by John Wiley & Sons Ltd.

Keywords

  • beta-lactoglobulin
  • farm effect
  • food for special medical purposes FSMP
  • holoBLG lozenge
  • immune resilience
  • immunomodulation

Fingerprint

Dive into the research topics of 'Micronutritional supplementation with a holoBLG-based FSMP (food for special medical purposes)-lozenge alleviates allergic symptoms in BALB/c mice: Imitating the protective farm effect'. Together they form a unique fingerprint.

Cite this